Skip to main content

Table 2 Administered dinaciclib dose levels and DLTs

From: A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

Dose level (mg/m2)

Number of subjects

Subjects with DLT in cycle 1

DLT

0.33

1

0

None

0.66

1

0

None

1.32

1

0

None

1.85

4

0

None

2.59

4

0

None

3.63

8

1

Hypokalemia, hypocalcemia, hypophosphatemia

5.08

3

0

None

7.11

7

1

Deep vein thrombosis

10

3

0

None

12

11

1

Septic shock

14

5

2

Orthostatic hypotension (1), elevated uric acid (1)